Unlock instant, AI-driven research and patent intelligence for your innovation.

BAFF receptor (BCMA), an immunoregulatory agent

An immunoglobulin and antibody technology, applied in the direction of antibodies, anti-inflammatory agents, non-central analgesics, etc.

Inactive Publication Date: 2013-04-17
BIOGEN MA INC +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This regulation is usually a "master switch" regulation, so that the signaling of the TNF family can lead to a large number of follow-up events with TNF as the most typical (best typified)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • BAFF receptor (BCMA), an immunoregulatory agent
  • BAFF receptor (BCMA), an immunoregulatory agent
  • BAFF receptor (BCMA), an immunoregulatory agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0138] Embodiment 1: Detect the combination of BAFF and BAFF-R with plate test

[0139] This Example describes the assay of BAFF binding to BAFF-R transfected cells using a plate assay.

[0140] The full-length human BAFF-R was prepared from BJAB polyA+RNA using the SuperscriptII pre-amplification kit (Life Technologies) to obtain a cDNA template, and primers complementary to the 5' and 3' end coding sequences of BAFF-R were used. Pful for amplification. The resulting PCR product was cloned into CH269, which was derived from pCEP4 (Invitrogen). The resulting clone was named pJST535. Human embryonic kidney cells (293EBNA) containing the EBNA-1 gene were inoculated into 6-well culture plates coated with fibronectin, and then passed lipofectamine with different concentrations of pJST535 and CH269 as background control (lipofectamine) (Life Technologies) for transfection. 48 hours after transfection, the ability of transfected cells to bind soluble flag-hBAFF (amino acids L83-...

Embodiment 2

[0142] Example 2: Determination of the binding of BAFF to BAFF-R transfected cells using a fluorescence activated cell sorter (FACS)

[0143] This example describes the detection of BAFF binding to BAFF-R transfected cells using a FACS assay.

[0144] Plasmid pJST535 encoding full-length BAFF-R was transfected into 293EBNA cells with FuGene6 (Boehringer Mannheim). At 24 hours or 48 hours after transfection, cells were removed from the plate with 5 mM EDTA in PBS and counted. Wash the cells with FACS buffer (PBS containing 10% fetal bovine serum, 0.1% NaN3 and 10 μg / ml hIgG (Jackson ImmunoResearch), and then take 2.5 × 10 5 Cells were incubated with flag-hBAFF diluted in FACS buffer at a concentration of 9 μg / ml to 0.037 μg / ml and incubated on ice for 1 hour. The above-mentioned cells were washed with FACS buffer, then placed on ice, and incubated with 5 μg / ml anti-FLAG monoclonal antibody M2 for 30 minutes. Wash the cells with FACS buffer, then place the cells on ice, and w...

Embodiment 3

[0146] Example 3: After the introduction of GFP markers, the interaction between BAFF / BAFF-R was determined by FACS

[0147] In this example, the binding of BAFF to cells co-transfected with BAFF-R and GFP reporter plasmids is described.

[0148] According to the method described in Example 2, 293EBNA cells were transfected with pJST535 and GFP reporter plasmids. The reporter plasmid encodes a membrane-anchored GFP molecule. Co-transfected with these two plasmids, we then analyzed the percentage of transfected cells capable of binding BAFF. The cells were taken out from the plate, combined with BAFF, and detected by the method described in Example 2. Also, to exclude dead cells, 7-AAD was introduced. Samples were analyzed by FACS and curves were drawn. The upper right quadrant represents those cells that incorporate BAFF (phycoerythrin positive) and express GFP.

[0149] Although not all GFP-transfected cells were able to bind BAFF, a significantly greater proportion of c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
fluorescenceaaaaaaaaaa
fluorescenceaaaaaaaaaa
Login to View More

Abstract

The invention relates to an antibody containing anti SEQ ID NO:1, anti amino acid 1-51 of SEQ ID NO:1 or anti amino acid 8-41 of SEQ ID NO:1 and a medicament composition for a pharmaceutical carrier and the use of the composition in preparation of medicaments for inhibiting B cell growth in mammal bodies, immunoglobulin production in mammal bodies, B cell growth and maturation induced by dendritic cells and treating autoimmune disease in mammal bodies, hypertension and B cell lymph hyperplasia diseases. The invention also provides a receptor in the TNF family: BAFF-R, further provides chimeric molecules and antibodies to BAFF-R and methods of use thereof.

Description

[0001] This case is a divisional application based on the invention application dated August 16, 2000, the Chinese application number is 00814288.2, and the invention name is "BAFF receptor (BCMA), an immunomodulator". field of invention [0002] The present invention relates to the use of BAFF receptor and its blocker in stimulating or inhibiting the expression of B cells and immunoglobulin, wherein BAFF is a beta-cell activating factor belonging to the tumor necrosis factor (TNF) family. The receptor can be used for anti-tumor and immune regulation, and can also be used for treating immunosuppressive diseases such as HIV. In addition, the receptors and their blockers are related to the development of hypertension and related diseases. In addition, cells transfected with the gene for the receptor can be used for gene therapy of tumors, lymphomas, autoimmune diseases or genetic diseases related to B-cells. Blocking agents, such as recombinant variants or antibodies specific f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/395A61P37/02A61P9/12A61P37/06A61P29/00A61KC07KC12N
Inventor 费比尼·麦凯杰弗里·布朗宁克里斯廷·安布罗斯朱尔格·肖普帕斯卡尔·施奈德杰弗里·汤普森
Owner BIOGEN MA INC